USA As Represented by Secretary of the Navy

Other

Temple University

Magainin Pharmaceuticals, Inc.

Inkine Pharmaceutical Company, Inc.

Inkine Pharmaceutical, Inc.

Taffy J Williams

Che-Hung Lee

Matthews O Bradley

George P Tuszynski

Glenn D Hoke

Paul Actor

Michael McLane

U Prasad Kari

Leonard S Jacob

Thomas M McKenna

Akindele O Johnson

John F Wong

Robert D Krell

Methods are presented for the therapeutic administration of angiocidin in the treatment of cancers such as glioma, breast cancer, and leukemia. Methods are also presented for inducing growth arrest and/or apoptosis of tumor cells, as well as inducing differentiation of tumor cells to inhibit tumorigenicity and to confer a non-tumor or healthy phenotype.

Administration of angiocidin for arresting the growth of a tumor cell

The present invention provides methods and compositions for treating cancer and chemotherapy-resistant cancers comprising a chemotherapeutic agent conjugated to or coadministered with a peptide.

Compositions for treating chemotherapy-resistant tumor cells and targeted chemotherapy compositions

Biologically active peptides with reduced toxicity in animals and a method for preparing same

The present invention relates generally to polypeptides that mimic or inhibit the biological activity of thrombospondin, and particularly to polypeptides in retroinverso form. These polypeptides may be used for their biological and pharmaceutical applications such as: (a) inhibiting the invasive and metastatic activity of melanoma cells, (b) promoting and inhibiting cellular attachment to tissue culture flacks, (c) promoting wound healing, angiogenesis, and implant acceptance, (d) agents for anti-platelet aggregation, (e) agents for antimalarial activity, and (f) diagnostic reagents in different therapeutic applications, as well as other related areas.

Retroinverso polypeptides that mimic or inhibit thrombospondin activity

Orally administered colonic purgative formulations and methods of its use for effecting partial or complete purgation of the colon in mammals, the formulations consisting of non-aqueous admixtures of a purgative salt selected from the group consisting of Mg.sub.3 (PO.sub.4).sub.2, MgHPO.sub.4, Mg(H.sub.2 PO.sub.4).sub.2, MgSO.sub.4, MgCl.sub.2, Na.sub.2 SO.sub.4, sodium tartrate, potassium tartrate, magnesium tartrate and mixtures, thereof, administered in tablet or capsule form in purgative effective concentrations. Preferred embodiments make use of at least one or more magnesium phosphate salts, more preferably dibasic magnesium phosphate; other preferred embodiments include the addition of binders, dispersants and buffers which do not adversely affect osmolality or effectiveness of the purgative formulations.

Non-aqueous colonic purgative formulations

Antisense oligonucleotides complementary to human mRNAs or pre-mRNAs coding or VCAM-I are used in a therapeutic treatment of sepsis (sepsis, the sepsis syndrome, septic shock and all other manifestations of the sepsis disease, including but not inclusive of, adult respiratory distress syndrome, multi-organ failure, or cardiovascular dysfunction).

Antisense oligonucleotides directed against human VCAM-1 RNA

The present invention provides a method for the treatment of septic shock d inflammatory complications of shock. A process for selectively inhibiting the expression of the human ELAM-I mRNA transcript using at least one oligonucleotide which is substantially complementary to at least a portion of the ELAM-I gene is disclosed, as are composition comprising the oligonucleotide.

Antisense oligonucleotides directed against human ELAM-I RNA

The present invention provides a method for the treatment of septic shock and inflammatory complications of shock. A process for selectively inhibiting the expression of the human ICAM-I mRNA transcript using at least one oligonucleotide which is complementary to at least a portion of the human ICAM-I mRNA is disclosed, as are oligonucleotides which are complementary to portions of the ICAM-I mRNA and compositions comprising the oligonucleotides.

Antisense oligonucleotides directed against human ICAM-I RNA

An agent and treatment for a subject susceptible to septic shock. The subject is treated with a PKC inhibitor, preferably wit a PKC inhibitor selected from the group consisting of lipid analogues. Preferred among the lipid analogues are sphingosine and its analogues. The inhibitors of this invention are administered, preferably by infusion in a suitable pharmaceutical carrier, in a range of 0.1 to 50 mg/Kg body weight preferably in the range of 0.5 to 25 mg/Kg body weight and most preferably in the range of 1 to 5 mg/Kg body weight.

Inhibitors of protein kinase C activity as protectors against septic

A novel immuno-dye reagent capable of detecting the presence of endotoxin in samples has been developed. The immuno-dye reagent comprises a solution of new methylene blue and an anti-endotoxin monoclonal antibody specific to a selected endotoxin. The immuno-dye reagent can be used in an assay to detect endotoxin by reacting the immuno-dye reagent with an endotoxin suspect pH adjusted sample, under hydrophobic conditions. The immuno-dye reagent can also be used in any application where binding of endotoxin is crucial, such as purifying endotoxin-contaminated solutions.

Growing community of inventors

Lansdale, PA, United States of America

Taffy J Williams